Product
TJ202
Aliases
TJ202 injection
3 clinical trials
3 indications
Indication
Systemic Lupus Erythematosus (SLE)Indication
Multiple Myeloma in RelapseIndication
Multiple MyelomaClinical trial
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients With Systemic Lupus ErythematosusStatus: Terminated, Estimated PCD: 2022-12-14
Clinical trial
A Phase 3, Randomized, Open-label, Parallel-controlled, Multi-center Study Comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Who Received at Least 1 Prior Line of TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
A Phase 2, Multi-center, Single-arm Study of TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Who Received at Least 2 Prior Lines of TreatmentStatus: Active (not recruiting), Estimated PCD: 2023-01-28